Company / Operating Margin
Apellis Pharmaceuticals, Inc. Operating Margin History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
5.5%
FY2025
5-year range
-805.7% / 5.5%
FY2021-FY2025
Trend
+126.1%
vs FY2024
Sector context
#49 of 136
Health Care
What the data says
At 5.5%, Apellis Pharmaceuticals, Inc.'s operating margin ranks #49 of 136 in the Health Care sector. Operating Margin has increased for 4 consecutive years, from -805.7% in FY2021 to 5.5% in FY2025.
Based on SEC 10-K filings.
5.5% in FY2025 with a 5-year CAGR of +90.8%.
Improved from -130.4% to 5.5% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +793.9pp
- 5-Year Change
- +90.8pp
- 10-Year Change
- -
Sector benchmark
#49 of 136 in Health CareTop 36% of 136This company 5.5% Sector average -778.9%
▼
+100.7% above sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s operating margin has grown for 4 consecutive years.
- In FY2025, operating margin increased 126.1% year-over-year.
- Currently 784.5pp above the Health Care sector average.
- Lowest operating margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 5.5% | +126.1% |
| FY2024 | -21.1% | +83.8% |
| FY2023 | -130.4% | +83.5% |
| FY2022 | -788.4% | +2.1% |
| FY2021 | -805.7% | -844.8% |
| FY2020 | -85.3% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026